Please try another search
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Name | Age | Since | Title |
---|---|---|---|
Nina Bhardwaj | - | - | Member of Scientific & Clinical Advisory Committee |
Shabnam Kazmi | - | 2023 | Independent Director |
Michael P. Bailey | 58 | 2020 | Independent Chairman |
Andrew Hall | - | 2020 | CEO & Director |
Kyle D. Kuvalanka | 55 | 2021 | Independent Director |
Saman Maleki | - | 2022 | Independent Director |
Brittany Davison | 33 | 2022 | Chief Accounting Officer, Corporate Secretary & Director |
Markus Warmuth | 52 | 2018 | Independent Director |
Michael Kalos | - | 2021 | Independent Director and Member of Scientific & Clinical Advisory Committee |
Jose L. Iglesias | 66 | - | Member of Scientific & Clinical Advisory Committee |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review